R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 58.41 CNY -2.81% Market Closed
Market Cap: 5.6B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Short-Term Debt
ÂĄ75.6k
CAGR 3-Years
25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Short-Term Debt
ÂĄ2.9B
CAGR 3-Years
8%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Short-Term Debt
ÂĄ556.1m
CAGR 3-Years
13%
CAGR 5-Years
6%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Short-Term Debt
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Short-Term Debt
ÂĄ2.8B
CAGR 3-Years
111%
CAGR 5-Years
44%
CAGR 10-Years
26%
W
WuXi XDC Cayman Inc
HKEX:2268
Short-Term Debt
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
5.6B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
57.24 CNY
Overvaluation 2%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Short-Term Debt?
Short-Term Debt
75.6k CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Short-Term Debt amounts to 75.6k CNY.

What is R&G PharmaStudies Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 3Y
25%

Over the last year, the Short-Term Debt growth was 50%. The average annual Short-Term Debt growth rates for R&G PharmaStudies Co Ltd have been 25% over the past three years .

Back to Top